Quality by Design - Planned Quality Management in Pharmaceutical Industry

被引:0
作者
Benes, Michal [1 ]
机构
[1] Univ Karlova Praze, Farmaceut Fak Hradci Kralove, Katedra Farmaceut Technol, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
来源
CHEMICKE LISTY | 2017年 / 111卷 / 09期
关键词
quality assurance; quality by design; design of experiment; process analytical technology; design space; BIOPHARMACEUTICALS; IMPLEMENTATION; DISSOLUTION; PRODUCT;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Quality by design is a systematic approach to drug product development and manufacturing that starts by defining the target product quality. It continues with an assessment of the risks to product quality that are involved in the characteristics of the raw materials and in the parameters of the manufacturing process. At the following stage, the actual impact of the characteristics and parameters identified is found through experiments and the design space is defined on that basis. Design space is an abstract multidimensional space in which the desired product quality can be attained by changing and controlling the variables. Based on the advanced knowledge of the product and the process obtained, the process can be optimized effectively and an appropriate control strategy set at points representing the greatest risk to quality or at points where information can be obtained well enough in advance to allow for reversing (by an appropriate adjustment of the process conditions) a potentially inappropriate course of the process. The information gained through the use of quality-by-design tools can then be used to accelerate the registration process of a new drug product and, in particular, for a substantial increase of manufacturing process efficiency and of the certainty that the desired product quality will be achieved.
引用
收藏
页码:559 / 566
页数:8
相关论文
共 22 条
[1]  
[Anonymous], 2006, GUID IND Q9 QUAL RIS
[2]  
Cogdill RP., 2008, Journal of Pharmaceutical Innovation, V3, P23, DOI [10.1007/s12247-008-9025-3, DOI 10.1007/s12247-008-9025-3, DOI 10.1007/S12247-008-9025-3]
[3]  
Cook J., 2014, PHARM SCI TECHNOL, V15, P140
[4]   AAPS Workshop on the Role of Dissolution in QbD and Drug Product Life Cycle: A Commentary [J].
D'Souza, Susan S. ;
Lozano, Ruben ;
Mayock, Stephen ;
Gray, Vivian .
DISSOLUTION TECHNOLOGIES, 2010, 17 (04) :41-45
[5]   Clinical relevance of dissolution testing in quality by design [J].
Dickinson, Paul A. ;
Lee, Wang Wang ;
Stott, Paul W. ;
Townsend, Andy I. ;
Smart, John P. ;
Ghahramani, Parviz ;
Hammett, Tracey ;
Billett, Linda ;
Behn, Sheena ;
Gibb, Ryan C. ;
Abrahamsson, Bertil .
AAPS JOURNAL, 2008, 10 (02) :380-390
[6]   Quality by design for biopharmaceuticals: a historical review and guide for implementation [J].
Elliott, Phillip ;
Billingham, Sam ;
Bi, Jingxiu ;
Zhang, Hu .
PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) :105-122
[7]  
Eziokwu N. V, 2014, IJCPR, V4, P110
[8]  
Kourti T., 2012, Pharm. Eng, V32, P52
[9]   A New Roadmap for Biopharmaceutical Drug Product Development: Integrating Development, Validation, and Quality by Design [J].
Martin-Moe, Sheryl ;
Lim, Fredric J. ;
Wong, Rita L. ;
Sreedhara, Alavattam ;
Sundaram, Jagannathan ;
Sane, Samir U. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (08) :3031-3043
[10]  
McConnell J., 2010, Journal of Validation Technology, V16, P30